Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

NCT05661201 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05661201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05661201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Lead sponsor
Georgetown University
Phase
Phase 1
Overall status
Recruiting
Start date
April 12, 2023
Completion date
January 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kras mutation-related tumors, solid tumor